The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers.
 
Alexander E. Drilon
Honoraria - AstraZeneca; Blueprint Medicines; Exelixis; Genentech/Roche; Ignyta; Loxo
Consulting or Advisory Role - ARIAD
Research Funding - Foundation Medicine
 
Thomas Filleron
No Relationships to Disclose
 
Isabella Bergagnini
No Relationships to Disclose
 
Julie Milia
No Relationships to Disclose
 
Vaios Hatzoglou
No Relationships to Disclose
 
Vamsidhar Velcheti
Honoraria - Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Merck; Novartis
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Foundation Medicine; Genentech; Genoptix; Merck
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); Trovagene (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Inivata (Inst); Lilly (Inst); Novartis (Inst); Onxeo (Inst); ose pharma (Inst); Pfizer (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - Sanomics Limited
Stock and Other Ownership Interests - Sanomics Limited
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Taiho Pharmaceutical (Inst)
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Pfizer
 
Juergen Wolf
No Relationships to Disclose
 
David P. Carbone
No Relationships to Disclose
 
D. Ross Camidge
No Relationships to Disclose
 
Gregory J. Riely
Consulting or Advisory Role - Genentech; Novartis; Novartis; Roche
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Novartis
 
Nir Peled
No Relationships to Disclose
 
Julien Mazieres
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; AstraZeneca; Genentech/Roche
Research Funding - Genentech/Roche (Inst); Puma Biotechnology (Inst)
 
Oliver Gautschi
No Relationships to Disclose